Nanotechnology Laboratory, Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt.
Sci Rep. 2018 Oct 25;8(1):15802. doi: 10.1038/s41598-018-34235-8.
The aim of this study was to utilize the biocompatibility of the natural ingredients zein and alpha lipoic acid (ALA) as a novel nanosphere matrix formulation that encapsulates vardenafil (VRD) for improved drug delivery and bioavailability. Three formulations were prepared using zein: ALA ratio of 1:1, 2:1 and 3:1 by liquid-liquid phase separation method. Physicochemical characterization and in vitro diffusion evaluation were carried out for the prepared formulations. A single dose clinical pharmacokinetic study was carried out for the selected formulation. Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively. Single dose clinical pharmacokinetic results, in healthy human volunteers, showed improved VRD bioavailability by 2.5 folds from nanosphere formula (F3) compared with the marketed tablets. The formulation of novel zein-ALA nanospheres offers the possibility for application of a biocompatible nano-carrier system in drug delivery for improved drug delivery and efficacy.
本研究旨在利用玉米醇溶蛋白和α-硫辛酸(ALA)的生物相容性,将其作为一种新型纳米球基质制剂,包封伐地那非(VRD),以提高药物递送和生物利用度。采用液-液相分离法,用玉米醇溶蛋白与 ALA 的 1:1、2:1 和 3:1 比例制备了三种制剂。对制备的制剂进行了理化性质表征和体外扩散评价,并对选定的制剂进行了单次剂量临床药代动力学研究。结果表明,VRD 制剂的粒径分别为 836.7±191.3、179.8±18.4 和 147.3±18.1nm,包封效率分别为 55.72±4.36%、65.33±7.82%和 69.38±6.83%,分别为 F1、F2 和 F3。单次剂量临床药代动力学结果显示,与市售片剂相比,新型玉米醇溶蛋白-ALA 纳米球制剂使 VRD 的生物利用度提高了 2.5 倍。新型玉米醇溶蛋白-ALA 纳米球制剂为生物相容性纳米载体系统在药物递送中的应用提供了可能性,以提高药物递送和疗效。